Walleye Capital
NVAX icon

Walleye Capital’s Novavax NVAX Stock Holding History

Walleye Capital’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$87.6K Buy
9,300
+9,000
+3,000% +$80.6K ﹤0.01% 3964
2026
Q1 		$2.44K Sell
300
-22,100
-99% -$200K ﹤0.01% 4229
2025
Q4 		$151K Sell
22,400
-124,800
-85% -$941K ﹤0.01% 3682
2025
Q3 		$1.28M Buy
147,200
+1,800
+1% +$14K ﹤0.01% 1907
2025
Q2 		$916K Buy
145,400
+96,400
+197% +$638K ﹤0.01% 2122
2025
Q1 		$314K Buy
49,000
+17,800
+57% +$147K ﹤0.01% 2922
2024
Q4 		$251K Buy
31,200
+10,400
+50% +$100K ﹤0.01% 3576
2024
Q3 		$263K Sell
20,800
-48,700
-70% -$629K ﹤0.01% 3809
2024
Q2 		$880K Buy
69,500
+65,300
+1,555% +$657K ﹤0.01% 2983
2024
Q1 		$20.1K Buy
+4,200
New +$19.5K ﹤0.01% 4929
2023
Q3 		– Sell
-9,500
Closed -$70.6K – 5184
2023
Q2 		$70.6K Sell
9,500
-14,100
-60% -$111K ﹤0.01% 3542
2023
Q1 		$164K Buy
23,600
+2,200
+10% +$20.2K ﹤0.01% 2621
2022
Q4 		$220K Sell
21,400
-5,000
-19% -$88.2K ﹤0.01% 1974
2022
Q3 		$480K Buy
+26,400
New +$1.14M 0.01% 1504

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Walleye Capital's NVAX Position: Q2 2026 in Review

Walleye Capital reduced its Novavax (NVAX) stake by 56% in Q2 2026, selling an estimated $191K and leaving 16,579 shares worth $156K. The position accounts for ﹤0.01% of the portfolio, ranked #3643.

Walleye Capital first reported a position in NVAX in Q1 2022 and has held it in 14 quarters since. The position peaked at $4.99M in Q2 2024. 267 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Walleye Capital held 16,579 shares of Novavax worth $156K as of Q2 2026.
  • Walleye Capital sold 21,341 Novavax shares in Q2 2026, an estimated $191K.
  • Novavax made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #3643 holding.
  • Walleye Capital first reported a position in Novavax in Q1 2022 and has held it in 14 quarters since.
  • Walleye Capital's Novavax position peaked at $4.99M in Q2 2024.
  • 267 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.